{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:00:05Z","timestamp":1791658805479,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40120-024-00669-8","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T06:01:58Z","timestamp":1728972118000},"page":"1535-1540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["What Is Combination Treatment in Migraine? Moving Toward a Uniform Definition of a Familiar Principle"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-2897","authenticated-orcid":false,"given":"Richard B.","family":"Lipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8106-4927","authenticated-orcid":false,"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0851-4914","authenticated-orcid":false,"given":"Andrew M.","family":"Blumenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"669_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.800605","volume":"12","author":"P Amiri","year":"2021","unstructured":"Amiri P, Kazeminasab S, Nejadghaderi SA, et al. Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol. 2021;12:800605.","journal-title":"Front Neurol"},{"issue":"4","key":"669_CR2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/j.1526-4610.2011.02058.x","volume":"52","author":"A Blumenfeld","year":"2012","unstructured":"Blumenfeld A, Gennings C, Cady R. Pharmacological synergy: the next frontier on therapeutic advancement for migraine. Headache. 2012;52(4):636\u201347.","journal-title":"Headache"},{"issue":"10","key":"669_CR3","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S1474-4422(22)00211-3","volume":"21","author":"EK Seng","year":"2022","unstructured":"Seng EK, Martin PR, Houle TT. Lifestyle factors and migraine. Lancet Neurol. 2022;21(10):911\u201321.","journal-title":"Lancet Neurol"},{"issue":"5","key":"669_CR4","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s40120-023-00529-x","volume":"12","author":"AM Blumenfeld","year":"2023","unstructured":"Blumenfeld AM, Lipton RB, Silberstein S, et al. Multimodal migraine management and the pursuit of migraine freedom: a narrative review. Neurol Ther. 2023;12(5):1533\u201351.","journal-title":"Neurol Ther"},{"issue":"2b","key":"669_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1590\/S0004-282X2000000300006","volume":"58","author":"AV Krymchantowski","year":"2000","unstructured":"Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr. 2000;58(2b):428\u201330.","journal-title":"Arq Neuropsiquiatr"},{"issue":"8","key":"669_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.1526-4610.2005.05178.x","volume":"45","author":"TR Smith","year":"2005","unstructured":"Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45(8):983\u201391.","journal-title":"Headache"},{"issue":"13","key":"669_CR7","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/jama.297.13.1443","volume":"297","author":"JL Brandes","year":"2007","unstructured":"Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007;297(13):1443\u201354.","journal-title":"JAMA"},{"issue":"suppl 1","key":"669_CR8","first-page":"30","volume":"60","author":"C O\u2019Gorman","year":"2020","unstructured":"O\u2019Gorman C, Jones A, Tepper SJ, Lipton RB, Tabuteau H. Efficacy and safety of AXS-07 (MoSEIC\u2122 meloxicam\/rizatriptan) in the acute treatment of migraine: results from the MOMENTUM phase\u00a03 trial [abstract]. Headache. 2020;60(suppl 1):30.","journal-title":"Headache"},{"issue":"2","key":"669_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/archneur.55.2.210","volume":"55","author":"RB Lipton","year":"1998","unstructured":"Lipton RB, Stewart WF, Ryan RE Jr, Saper J, Silberstein S, Sheftell F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol. 1998;55(2):210\u20137.","journal-title":"Arch Neurol"},{"issue":"1","key":"669_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/head.12499","volume":"55","author":"MJ Marmura","year":"2015","unstructured":"Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3\u201320.","journal-title":"Headache"},{"issue":"4","key":"669_CR11","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1526-4610.2011.02039.x","volume":"52","author":"F Derosier","year":"2012","unstructured":"Derosier F, Sheftell F, Silberstein S, et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache. 2012;52(4):530\u201343.","journal-title":"Headache"},{"issue":"6","key":"669_CR12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.55.6.754","volume":"55","author":"SD Silberstein","year":"2000","unstructured":"Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754\u201362.","journal-title":"Neurology"},{"issue":"6","key":"669_CR13","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/0333102413515342","volume":"34","author":"V Tullo","year":"2014","unstructured":"Tullo V, Valguarnera F, Barbanti P, et al. Comparison of frovatriptan plus dexketoprofen (25\u00a0mg or 37.5\u00a0mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: a randomized study. Cephalalgia. 2014;34(6):434\u201345.","journal-title":"Cephalalgia"},{"issue":"2","key":"669_CR14","doi-asserted-by":"publisher","first-page":"333102422114377","DOI":"10.1177\/03331024221143773","volume":"43","author":"I de Boer","year":"2023","unstructured":"de Boer I, Verhagen IE, Souza MNP, Ashina M. Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies. Cephalalgia. 2023;43(2):3331024221143773.","journal-title":"Cephalalgia"},{"issue":"3","key":"669_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/nedt.2006.2.3.293","volume":"2","author":"AV Krymchantowski","year":"2006","unstructured":"Krymchantowski AV. The use of combination therapies in the acute management of migraine. Neuropsychiatr Dis Treat. 2006;2(3):293\u20137.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"669_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.annemergmed.2004.07.430","volume":"45","author":"I Colman","year":"2005","unstructured":"Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature. Ann Emerg Med. 2005;45(4):393\u2013401.","journal-title":"Ann Emerg Med"},{"issue":"1","key":"669_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2514183X18823377","volume":"3","author":"H Diener","year":"2019","unstructured":"Diener H, Holle-Lee D, N\u00e4gel S, et al. Treatment of migraine attacks and prevention of migraine: guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin Transl Neurosci. 2019;3(1):1\u201340.","journal-title":"Clin Transl Neurosci"},{"issue":"6\u20137","key":"669_CR18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.neurol.2016.06.005","volume":"172","author":"X Moisset","year":"2016","unstructured":"Moisset X, Mawet J, Guegan-Massardier E, et al. French guidelines for the emergency management of headaches. Rev Neurol (Paris). 2016;172(6\u20137):350\u201360.","journal-title":"Rev Neurol (Paris)"},{"issue":"1","key":"669_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/head.12961","volume":"57","author":"ZA Ahmed","year":"2017","unstructured":"Ahmed ZA, Nacopoulos DA, John S, Papesh N, Levine D, Bamford CC. An algorithm for opioid and barbiturate reduction in the acute management of headache in the emergency department. Headache. 2017;57(1):71\u20139.","journal-title":"Headache"},{"issue":"7","key":"669_CR20","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3949\/ccjm.85a.17049","volume":"85","author":"AS Ali","year":"2018","unstructured":"Ali AS, Stillman M. What inpatient treatments do we have for acute intractable migraine? Cleve Clin J Med. 2018;85(7):514\u20136.","journal-title":"Cleve Clin J Med"},{"issue":"13","key":"669_CR21","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1212\/WNL.0b013e31824d5846","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Dodick DW, Lindblad AS, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology. 2012;78(13):976\u201384.","journal-title":"Neurology"},{"issue":"1","key":"669_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15360288.2020.1829249","volume":"35","author":"M Armanious","year":"2020","unstructured":"Armanious M, Khalil N, Lu Y, Jimenez-Sanders R. Erenumab and onabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis. J Pain Palliat Care Pharmacother. 2020;35(1):1\u20136.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"9","key":"669_CR23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1177\/03331024221082077","volume":"42","author":"D Chowdhury","year":"2022","unstructured":"Chowdhury D, Mundra A, Datta D, Duggal A, Krishnan A, Koul A. Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: a randomized controlled trial. Cephalalgia. 2022;42(9):859\u201371.","journal-title":"Cephalalgia"},{"issue":"10","key":"669_CR24","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1111\/head.14010","volume":"60","author":"MT Minen","year":"2020","unstructured":"Minen MT, Adhikari S, Padikkala J, et al. Smartphone-delivered progressive muscle relaxation for the treatment of migraine in primary care: a randomized controlled trial. Headache. 2020;60(10):2232\u201346.","journal-title":"Headache"},{"key":"669_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.852616","volume":"13","author":"T Klan","year":"2022","unstructured":"Klan T, Gaul C, Liesering-Latta E, et al. Efficacy of cognitive-behavioral therapy for the prophylaxis of migraine in adults: a three-armed randomized controlled trial. Front Neurol. 2022;13: 852616.","journal-title":"Front Neurol"},{"issue":"2","key":"669_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/head.13738","volume":"60","author":"MT Minen","year":"2020","unstructured":"Minen MT, Sahyoun G, Gopal A, et al. A pilot randomized controlled trial to assess the impact of motivational interviewing on initiating behavioral therapy for migraine. Headache. 2020;60(2):441\u201356.","journal-title":"Headache"},{"issue":"24","key":"669_CR27","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1001\/jama.2013.282533","volume":"310","author":"SW Powers","year":"2013","unstructured":"Powers SW, Kashikar-Zuck SM, Allen JR, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA. 2013;310(24):2622\u201330.","journal-title":"JAMA"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00669-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00669-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00669-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T12:27:01Z","timestamp":1730896021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00669-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["669"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00669-8","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"19 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Richard B. Lipton, MD, serves on the editorial boards of <i>Neurology<\/i> and <i>Cephalalgia<\/i> and is a senior advisor for <i>Headache<\/i>. He has received research support from the National Institutes of Health. He also receives support from the Migraine Research Foundation and the National Headache Foundation. He has reviewed for the National Institute on Aging and National Institute of Neurological Disorders and Stroke; serves as consultant, advisory board member, or has received honoraria or research support from AbbVie, Aeon, Amgen, Biohaven, Dr. Reddy\u2019s Laboratories, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Teva, Vector, and Vedanta Research. He receives royalties from <i>Wolff\u2019s Headache<\/i>, 8th edition (Oxford University Press, 2009), and Informa. He holds stock or options in Axon, Biohaven, CoolTech, Manistee, and Wizermed. Jessica Ailani, MD, has served as a consultant for AbbVie, Aeon, Amgen, Biohaven, Dr. Reddy, Eli Lilly, GlaxoSmithKline, Gore, Impel, Ipsen, Linpharma, Lundbeck, Merz, Miravo, Nesos, Neurolief, Pfizer, Scilex, Satsuma, Teva, Theranica, and Tonix; received stock options from Ctrl M; provided editorial services to <i>Current Pain and Headache Reports<\/i>, SELF, and Medscape; and received clinical trial support from AbbVie, Biohaven, Eli Lilly, Parema, Satsuma, and Zosano. Andrew M. Blumenfeld, MD, has served on advisory boards for, consulted for, and\/or been a speaker or contributing author for AbbVie, Aeon, Alder, Allergan, Amgen, Axsome, Biohaven, Equinox, Lilly, Lundbeck, Novartis, Revance, Teva, Theranica, and Zosano. He has received grant support from AbbVie and Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}